- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease Severe chronic plaque psoriasis
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 431KB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 70KB)
Ustekinumab – July 2022
Ustekinumab (Severe Crohn disease; Severe chronic plaque psoriasis): Injection 90 mg in 1 mL pre-filled syringe; Stelara®
Last updated
28 October 2022